TOKYO -- A Chinese lab attempting to patent the use of anti-flu drug Avigan for the treatment of COVID-19 is facing pushback in Japan, where the medicine was originally developed.
The Beijing-based Academy of Military Medical Sciences obtained a patent for the use of favipiravir, the chemical compound behind Avigan, in China earlier this year, and has applied for similar intellectual property rights in Japan, the U.S. and Europe.
